Table of Contents Categories
  Encyclosphere.org ENCYCLOREADER
  supported by EncyclosphereKSF

Sangamo Therapeutics

Topic: Company

 From HandWiki - Reading time: 4 min

Sangamo Therapeutics
TypePublic
OTCQB: SGMO
IndustryBiotechnology
Founded1995
Headquarters
Richmond, California, US
Key people
Sandy Macrae (CEO)
RevenueIncrease $111.3 million[1] (2022)
Increase -$201.281 million[1] (2022)
Increase $192.3 million[1] (2022)
Total assetsDecrease $562.5 million[1] (2022)
Total equityDecrease $294.958 million[1] (2022)
Number of employees
354
Websitesangamo.com
Footnotes / references
[1]
President and CEO Sandy Macrae in 2018

Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Richmond, California, that develops cell and gene therapies for severe genetic diseases.[2]

History

The company was founded in 1995 in Richmond, California.[3] It was originally known as Sangamo Biosciences, Inc. before changing its name in 2017. In September 2018, it had 182 employees.[3] Alexander (Sandy) Macrae, a physician-scientist who previously held senior roles at Takeda Pharmaceuticals and GlaxoSmithKline, is Sangamo's CEO and president.[4]

Sangamo Therapeutics' Sangamo name and, for a brief time, its logo, were taken from the earlier Sangamo Electric Company, founded as an offshoot of the Illinois Watch Company in January 1899, the name coming from the nearby Sangamon River.[5][6] The modern Sangamo's founder, Edward Oliver Lanphier II, is the great-grandson of one of Sangamo Electric's founders, Robert Carr Lanphier Sr.

In June 2026, Sangamo Therapeutics filed for Chapter 11 bankruptcy, retaining Raymond James & Associates as its restructuring advisor. Its bankruptcy petition estimated assets and liabilities each between $100 million and $500 million.[7]

Research

Sangamo's clinical development programs have emerged from proprietary zinc finger and serine integrase gene editing technologies that the company has developed, coupled with its proprietary adeno-associated virus (AAV)-based delivery platform.[8][9] The company's clinical pipeline includes investigational treatments for haemophilia A; lysosomal storage diseases including Fabry disease, mucopolysaccharidosis type I (Hurler Syndrome), and mucopolysaccharidosis type II (Hunter Syndrome); and neurological disorders including small fiber neuropathy (SFN) and prion disease.[10]

The FDA granted Sangamo fast track designation for Giroctocogene fitelparvovec (formerly known as SB-525), a gene therapy candidate for haemophilia A. In its partnership with Pfizer in 2017,[11] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.[2]

In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter syndrome.[12] As of February 2019 clinical trials by Sangamo involving gene editing using zinc finger nuclease were ongoing.[13]

Clinical trials

Sangamo's programs are a mix of wholly owned and partnered; major partners include Pfizer, Biogen, Sanofi, Takeda, and Kite (a Gilead company).[14][2][15][16]

As of 2020 Sangamo had the following clinical trials underway in the US:

In February 2023, Sangamo Therapeutics announced that it would stop the late-stage development for the Phase 1/2 PRECIZN-1 study of BIVV003 its sickle cell drug.[24]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results". Sangamo. 22 February 2023. https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-reports-recent-business-highlights-and-5. 
  2. ↑ 2.0 2.1 2.2 McConaghie, Andrew (2017-05-17). "Sangamo and new gene therapy partner Pfizer lifted by FDA fast track" (in en-GB). Pharmaphorum. https://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/. 
  3. ↑ 3.0 3.1 "Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04" (in en-US). Equities. 2018-09-08. https://www.equities.com/news/sangamo-therapeutics-inc-sgmo-moves-higher-on-volume-spike-for-september-04. 
  4. ↑ Ledford, Heidi (2018-09-05). "First test of in-body gene editing shows promise" (in EN). Nature. doi:10.1038/d41586-018-06195-6. ISSN 0028-0836. http://www.nature.com/articles/d41586-018-06195-6. 
  5. ↑ "Sangamo: A History of Fifty Years". https://ia801307.us.archive.org/18/items/sangamohistoryof00lanp/sangamohistoryof00lanp_bw.pdf. 
  6. ↑ "The History of Sangamo Electric Company". http://www.sangamoclocks.com/history. 
  7. ↑ "Sangamo Therapeutics (SGMO) Files for Chapter 11 Bankruptcy Protection" (in en). 2026-06-23. https://www.gurufocus.com/news/8927328/sangamo-therapeutics-sgmo-files-for-chapter-11-bankruptcy-protection. 
  8. ↑ "Sangamo has its finger on the next evolution of gene editing". https://www.pharmavoice.com/news/sangamo-sandy-mcrae-gene-editing-zinc-finger/621283/. 
  9. ↑ Renauer, Cory (2018-09-06). "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?" (in en). The Motley Fool. https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx. 
  10. ↑ "Programs". https://www.sangamo.com/programs/. 
  11. ↑ "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer". https://www.pfizer.com/news/press-release/press-release-detail/sangamo_therapeutics_and_pfizer_announce_collaboration_for_hemophilia_a_gene_therapy. 
  12. ↑ Marchione, Marilyn (7 February 2019). "Tests suggest scientists achieved 1st 'in body' gene editing". AP News. https://www.apnews.com/d728f86d70d94ce68dd4fedffe58d03f. 
  13. ↑ Staff (2 February 2019). "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II". U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03041324. 
  14. ↑ "SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters" (in en). https://www.reuters.com/companies/SGMO.OQ. 
  15. ↑ "Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates" (in en). https://www.fiercebiotech.com/biotech/sangamo-shares-jump-pfizer-sanofi-and-its-own-gene-and-cell-therapy-updates. 
  16. ↑ "Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news.". https://en.hdbuzz.net/275. 
  17. ↑ "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03432364. 
  18. ↑ "Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT04046224. 
  19. ↑ "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03653247. 
  20. ↑ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03041324. 
  21. ↑ "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02702115. 
  22. ↑ "Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT03061201. 
  23. ↑ "Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02695160. 
  24. ↑ "Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans" (in en). Fierce Biotech. 2023-02-23. https://www.fiercebiotech.com/biotech/sangamo-shelves-sickle-cell-therapy-joining-rivals-forced-rethink-development-plans-disease. 

[ ⚑ ] 37°40′36″N 122°23′03″W / 37.67669°N 122.38421°W / 37.67669; -122.38421



Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Sangamo_Therapeutics&oldid=4594321"
Licensed under CC BY-SA 3.0 | Source: https://handwiki.org/wiki/Company:Sangamo_Therapeutics
39 views | Status: cached on October 04 2026 02:34:17
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF